The End Of Steroids? NEW MUSCLE DRUGS Are Here

Summary by Krater

Dr. Mike Israetel reviews a Regeneron Pharmaceuticals preclinical study on monkeys evaluating the effects of non-androgenic anabolic drug combinations—specifically semaglutide, trevogrumab, and garetosmab—on fat loss and muscle retention. He concludes that these dual- and triple-therapy drug combinations can radically improve body composition by promoting significant fat loss while simultaneously preserving or even increasing muscle mass without androgenic side effects.

From the video

Answers: What are the effects of non-androgenic anabolic drugs like myostatin and activin-A blockers combined with semaglutide on fat loss and muscle growth?

• non-androgenic anabolics
• myostatin antagonists
• activin-A antagonists
• semaglutide weight loss
• muscle retention during fat loss
• animal clinical trials in pharmacology
• future of physique enhancement

What it concludes

• Monkeys dieting with semaglutide lost about 700g of body fat and about 100g of muscle.
• Monkeys dieting with semaglutide and the myostatin blocker trevogrumab lost about 1300g of body fat and about 15g of muscle.
• Monkeys with semaglutide, trevogrumab, and garetosmab lost about 1400g of body fat and gained about 450g of muscle over 20 weeks.
• These non-androgenic drug combinations are currently in Phase 2 clinical trials for humans.
• These drug therapies are expected to be available around 2027 to 2028 following FDA approval and will radically transform physique enhancement without androgenic side effects.